Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis.
Kohlmann R, Salmen A, Chan A, Knabbe C, Diekmann J, Brockmeyer N, Skaletz-Rorowski A, Michalik C, Gold R, Überla K